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ABSTRACT 
THE EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 , DOCOSAHEXAENOIC ACID 
AND 5-FLUOROURACIL ON HUMAN BREAST CANCER CELLS 
by 
Liv Astri Engelsen 
May 2012 
It is well documented that vitamin D and DHA have antiproliferative effects on a 
variety of human cancers, including breast cancer. Studies have shown that a combination 
approach to cancer treatment is more effective than any one treatment administered 
alone. In this study, human mammary epithelial cells from the MCF-7 cell line were 
treated with 25 µM DHA, 1 µM calcitriol, and 15 µM 5-Fluorourocil alone and in 
multiple combinations for 72 hours. Both DHA and 5-Fluorouracil slowed growth 
significantly (p < 0.05). In contrast, vitamin D did not inhibit cell growth at 1 µM. The 
combination of vitamin D and DHA inhibited cell growth slightly more than DHA alone. 
Interestingly, DHA was just as effective as 5-Fluorouracil at inhibiting cell growth. These 
results suggest that DHA may be just as efficacious as 5-Fluorouracil in slowing breast 
cancer progression and therefore may suggest a dietary approach to breast cancer 
treatment with low toxicity. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Introduction 
Cancer broadly describes a large number of disease types all characterized by 
uncontrolled cell division and regulation. Currently one in four deaths (approximately 
1500 per day) occur as a result of cancer, making it the second cause of death in the 
United States (Jemal et al., 2010). The process of cancer development, carcinogenesis, 
occurs in three steps - initiation, promotion and progression. During the initiation stage, 
the DNA within a cell is altered. This can be a result of an environmental insult (exposure 
to a carcinogen) which can result in the formation of free radicals that can cause damage 
to many parts of the cell, including the DNA. In the promotion stage, the damaged cells 
begin to divide at an uncontrollable rate resulting in tumor formation. The tumor may 
then either remain benign and contained, or it may enter the progression stage in which 
metastasis occurs and the cells infect other healthy tissues of the body. 
Under normal conditions, there are several mechanisms in place that keep cell 
division tightly regulated. Some of these controls are genetic or hormonal, often 
involving growth factors such as interleukins and cytokines, or chemical signals from 
other cells. Two types of genetic mechanisms involve genes called oncogenes and tumor-
suppressor genes. While oncogenes turn on the signal for cell growth, suppressor genes 
turn it off (Nelms et al., 2007). An important protein involved in the normal cell cycle 
process is p53, which is a tumor suppressor gene that prevents cells with damaged DNA 
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from dividing until the DNA is repaired. Known as the "guardian" of the genome, this 
protein exerts its effects by upregulating the gene p21 which inhibits cyclin-dependent 
kinase (CDK). Once the cell cycle is disrupted by these proteins, DNA can then be 
repaired or the cell can be stimulated to undergo apoptosis (Ford et al., 2004). 
Unfortunately, p53 is suppressed in many tumors and completely inactivated in about 
half of all cancer cases (Levine, 1997). In fact, p53 mutations occur in breast cancer cases 
only about 30% of the time, which is much lower than some other cancer types. In many 
of the breast cancer cases in which a mutation does not occur, p53 is removed from the 
nucleus and compartmentalized in the cytoplasm of the cell, known as nuclear exclusion, 
where it is completely inactivated (Moll et al., 1992). 
Apoptosis, or programmed cell death, is a process that normal cells undergo to 
prevent damaged cells from reproducing and is vital to eukaryotic life. The main groups 
of molecules that play a major role in the process of apoptosis include caspases, Bcl-2 
proteins, members of the tumor necrosis factor receptor (TNF-R) superfamily, and p53 
(Pardee, 2004). Apoptosis is carried out by caspases and nucleases which are activated by 
Bax (pro-apoptosis) and deactivated by Bcl-2 (pro-survival) proteins (Pardee, 2004). 
Caspases are proteases that cleave a number of proteins, which can either activate or 
inactivate them. These cysteine proteases exist as zymogens within the cell and must be 
activated under apoptotic conditions (Wang & El-Deiry, 2004). Out of the 11 caspases in 
humans, 7 of them are closely involved in regulating apoptosis (Reed & Green, 2011 ). 
Initiator caspases (2, 8, 9, and 10) activate effector caspases (3, 6, and 7) which induce a 
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cascade of activation. Once activated, effector caspases inactivate a variety of cellular 
proteins, ultimately killing the cell (Wang & El-Deiry, 2004). 
Carcinogenesis occurs when many of these anticancer regulatory mechanisms are 
breached simultaneously. Researchers have identified six key physiological mutations 
within the cell that are required for cancer development and tumorigenesis (see Table 1 ). 
These mutations are similar in most, if not all cancer types and can arise at various times 
during this multi-step process (Hanahan & Weinberg, 2000). 
T bl 1 Th . h II k bT. . I . (H h & W. b a e : e SIX a mar capa 1 1t1es essentia to tumongenes1s. ana an em erg, 2000) 
Component Acquired Capability Example of Mechanism 
1 Self-sufficiency in growth Activate H-Ras oncogene 
signals 
2 Insensitivity to antigrowth Lose retinoblastoma suppressor 
signals 
3 Evading apoptosis Produce insulin-like growth factor 
survival factors 
4 Limitless replicative potential Turn on telomerase 
5 Sustained angiogenesis Produce VEGF inducer 
6 Tissue invasion and metastasis Inactivate E-cadherin 
Breast Cancer 
Breast cancer is the most frequently diagnosed type of cancer in women and is 
among the most lethal. An estimated 207,090 women were diagnosed with breast cancer 
in 2010 in the United States, which accounts for 28% of all new cancer cases in this 
group. Death rates from breast cancer have been steadily declining in North America 
since the early 1990s largely due to early detection and current treatment efforts. 
However, breast cancer remains the leading cause of cancer-related death among women 
between the ages of20 and 59 (Jemal et al., 2011; Jemal et al., 2010). 
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Over half of all breast cancer cases are in industrialized countries, and rates are 
nearly five times higher in Western countries than in developing countries and Japan, an 
observation supporting the role of environmental factors in carcinogenesis. Migrant 
studies have further supported that these factors play a major role in the onset of breast 
cancer since a woman's risk for developing breast cancer typically increases when she 
moves from a developing country (or from Japan) to the US or Canada (AICR/WCRF). 
Although epidemiological studies show correlations between cancer rates and certain 
dietary factors, it is challenging to label a single food or drink as a carcinogen. Relating a 
specific nutrient deficiency to carcinogenesis is equally difficult due to the large number 
of environmental factors that may play a contributing role (Nelms et al., 2007). For 
example, an earlier age of menarche and post-menopausal obesity are more common in 
Western cultures, both of which increase estrogen levels, a hormone that has been linked 
to the development of breast cancer (AICR/WCRF). 
Characterized by estrogen-dependent growth, breast cancer progression is most 
often dependent on proliferation of breast cancer cells that occurs through the estrogen 
receptors (ER) of the cell, which are classified as steroid receptors in the nuclear receptor 
superfamily (Mangelsdorf et al., 1995). While the role of ER~ receptors in breast cancer 
is unclear, the estrogen receptor ERa is an important marker for breast cancer diagnosis 
and prognosis. About one third of all breast cancer cases are ERa negative which are 
known to have a poorer prognosis than those that are ERa positive (Osborne, 1998; 
Jensen, 2004). 
A tumor suppressor gene known as breast cancer gene 1 (BRCA 1) plays an 
important role in mammary carcinogenesis. Mutations in the BRCAl and BRCA2 genes 
have been linked to a poor prognosis for recovery in breast cancer cases, and complete 
loss of BRCAl results in DNA replication errors that can facilitate other malignancies 
(Madjd et al., 2011). Genetic inheritance of a mutant BRCAl or BRCA2 gene correlates 
with an estimated lifetime risk for breast cancer of roughly 78% (Brose et al., 2002). 
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Once a breast tumor metastasizes, quality of life and duration of survival count on 
the patient's sensitivity to the chemotherapy treatments. The efficacies of such treatments 
are typically dose-dependent, which is often limited due to the high level of side effects 
from radiation and chemotherapy drugs. Any supplemental and non-toxic treatment with 
the potential to increase tumor sensitivity to anti-cancer drugs could contribute to a 
favorable prognosis and treatment outcome (Bougnoux et al., 2009). 
Litrerature Review 
Vitamin D 
Though technically a prohormone, vitamin D is well known for its important role 
in bone formation and calcium homeostasis (DeLuca, 2004). Although it can be absorbed 
through the skin from UVB radiation and then hydroxylated to the metabolically active 
form in the liver and kidneys, vitamin D deficiency is still prevalent in the United States 
(Stiff & Miller, 2009). This is partially due to the fact that between October and March, 
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the amount of ultraviolet radiation from the sun is inadequate in any location above 35° 
latitude, which includes about two-thirds of the U.S. It is logical that most adults in the 
U.S., especially those who live in the northern regions, have insufficient levels (21 ng/mL 
to 29 ng/mL) of serum vitamin D (Stiff & Miller, 2009). Although vitamin D can be 
consumed in the diet, it is only found naturally in seafood, mushrooms, and egg yolks, so 
nutritional supplementation is generally recommended (Moyad, 2009). 
The Institute of Medicine (IOM) updated the recommended dietary allowances 
(RDA) for vitamin Din November of 2010, but recommended levels fall short of the 
amounts required for optimal health, according to many professionals (see Table 2). This 
is partially due to the fact that the IOM made the recommendations based on the 
appropriate levels of vitamin D necessary for bone health since evidence for the role of 
vitamin D in the prevention of cancer, cardiovascular disease, diabetes, and other 
autoimmune disorders is inconclusive (Ross et al., 2011 ). The RDA for vitamin D for 
individuals between the ages of 1 and 70 is currently 600 IU/day, which corresponds with 
a serum level of 20 ng/ml (50 nmol/L). Many experts believe a more appropriate 
recommendation for vitamin D would be in the range of 1000-2000 IU/day, especially in 
locations north of the equator. It is estimated that the body's daily requirement of vitamin 
D is around 3000-5000 IU/day (Heaney et al., 2003). 
Table 2: Assessment of serum 25(0H)D levels for health (Holick 2009) , 
Deficient Insufficient Optimal Toxic 
<20 ng/ml 21-29 ng/ml >30 ng/ml > 150-200 ng/ml 
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Vitamin D functions through the vitamin D receptor (VDR) of human cells. Once 
believed to be present only in cells involved in bone formation, VDRs are now known to 
be present in nearly every nucleated cell in the human body, including mammary cells. 
Along with their ligands, VDRs control proliferation, apoptosis and differentiation at 
different stages in cellular development (Welsh, 2007). VDRs belong to the nuclear 
receptor superfamily and provide a link between signaling molecules on the cell surface 
and gene transcription factors within the cell. When calcitriol, the active form of vitamin 
D, binds to the VDR, it forms a dimer complex with another receptor known as retinoid 
X receptor (RXR). This complex then binds to vitamin D response elements (VDREs) 
which are specific DNA sequences of target genes, allowing transcription to occur (Ma, 
et al., 201 O; Colston & Hansen, 2001 ). Through this regulation of gene expression, 
vitamin D is able to maintain the differentiated phenotype of mammary cells and allows it 
to possibly play a role in the prevention and treatment of breast cancer (Welsh, 2007). 
The relationship between vitamin D status and disease onset and prognosis has 
been a recent area of interest in all levels of research. Many studies have suggested that 
there is a negative relationship between vitamin D status and breast cancer risk (Abbas et 
al., 2008; Crew et al., 2009; Rejnmark et al., 2009) although other studies have failed to 
establish this relationship (Chlebowski et al., 2008; Freedman et al., 2008; McCullough et 
al., 2009). A case control study comparing 701 cancer cases to 724 matched controls 
revealed that women with high levels of serum 1,25(0H)D, and possibly 1,25(0H)2D, 
were at a low risk of developing breast cancer, and this was especially evident in women 
over 60 years of age (Bertone-Johnson et al., 2005). One study looking at data from 
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NHANES III observed no relationship between vitamin D status and cancer death, but 
did find that individuals with vitamin D levels of <17.8 ng/ml had a 26% higher risk of 
all-cause mortality (Melamed et al., 2008). Other studies have indicated that the lowest 
number of cancer mortalities occurred in cancer cases that were diagnosed during the 
summer and fall, when serum vitamin D3 levels are typically the highest (Robsahm et al., 
2004; Lim et al., 2006). A randomized placebo controlled trial in 2007 gave 1179 post-
menopausal women either calcium supplementation ( 1400-1500 mg), calcium plus 
vitamin D (1100 IU), or a placebo each day and followed them for 4 years. They 
discovered that the rate of cancer diagnosis was significantly lower in the calcium plus 
vitamin D group than the calcium or control group. The findings suggest that increasing 
dietary intake of calcium and vitamin D decreases cancer risk in this population (Lappe et 
al., 2007). 
Research has consistently found that vitamin D exhibits antitumor effects on 
breast cancer cells in vitro, mainly by inducing apoptosis, but also through proliferation 
inhibition (Deeb et al., 2007). One study showed that apoptosis is induced within 48 
hours in MCF-7 cells treated with 100 nM of l,25(0H)iD3 (Welsh, 1994). Lower 
concentrations appear to be effective at reducing cell viability as well and MCF-7 cells 
exhibited growth inhibition after 96 hours of treatment at concentrations ranging from 10 
to 100 nM/L 1,25(0H)2D3 (Kemmis et al., 2006). A similar study compared the effects of 
1,25(0H)2D3 to a low calcemic vitamin D analog on MCF-7 cells. They discovered that 
both compounds reduced the number of viable cells in a dose and time dependent 
manner, and that the vitamin D analog was 50 times more effective than 1,25(0H)2D3 
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(Simboli-Campbell et al., 1997). Researchers in Denmark discovered that vitamin D and 
their analogues both slowed the growth and induced apoptosis of human MCF-7 breast 
cancer cells. Interestingly, these effects occurred independently of caspase activation and 
p53, while overexpression of Bcl-2 protected the cells from apoptosis (Mathiasen et al., 
1999). In another study, MCF-7 cells were pre-treated with the polyphenols resveratrol 
(from red wine) and genistein (from soy) to mimic the effects of estrogen and increase 
VDR expression prior to treatment with 100 nM calcitriol. The researchers found that 
both phytoestrogens increased cellular sensitivity to vitamin D, but more so with 
reservatrol (Wietzke & Welsh, 2003). 
The MCF-7 cell line is characterized by a phenotype that is estrogen-receptor 
(ER) positive and therefore may be more responsive to treatment. Comparison of the 
effects of l ,25(0H)2D3 on ER+ cells (MCF-7) and ER- cells (MDA MB 231) resulted in 
antiproliferative effects that occurred by different genetic mechanisms, but these effects 
were much stronger in the MCF-7 cells. The mechanisms by which apoptosis was 
induced in the MCF-7 cell line included the upregulation ofp53, p21-activated kinase 
(PAC-1), and caspases (Swami et al., 2003). Researchers discovered that vitamin D 
downregulates ER levels in the MCF-7 cell line which could play an important role in its 
antiproliferative actions (Swami et al., 2000). 
Due to the fact that high levels of vitamin D are required to obtain anti-cancer 
effects in vitro, few clinical trials have used quantities large enough to produce similar 
results out of fear of inducing hypercalcemia. Daily oral dosing of 0.5 µg to 1.5 µg 
induced hypercalcemia and did not improve patient prognosis in a sample of 14 subjects 
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with advanced prostate cancer (Osborn et al., 1995). However, several studies have 
established that adequate doses of calcitriol can in fact be safely administered if it is done 
. 
in an intermittent manner (Ma et al., 2010). In one study, oral calcitriol was given to 15 
patients with refractory malignancies on a weekly basis for 20 cycles of therapy. Weekly 
dosing in this manner up to 2. 8 µg/kg per week was effective and resulted in minimal 
toxicity. A plateau was observed in calcitriol concentrations at about 0.48 µg/kg and peak 
serum calcitriol concentrations ranged from 3.7 to 6.0 nM (Beer et al., 2001). 
DHA 
Docosahexaenoic Acid (DHA) is an omega-3 polyunsaturated fatty acid (PUF A) 
that is not only vital to proper visual and neurological development, but has been 
implicated in the treatment and prevention of many diseases, including cancer (Head, 
2009). Both omega-3 and omega-6 fatty acids are considered to be essential fatty acids 
(EF As) and must be consumed in the diet. These fatty acids are not interchangeable in the 
body because humans lack the enzyme omega-3 desaturase, which is necessary to convert 
n-6 to n-3 (Simopoulos, 2006). DHA is one of the three major n-3 FAs, the other two 
being eicosapentaenoic acid (EPA) and a-linolenic acid (ALA) (Hardman, 2002). The 
best dietary source of DHA and EPA is fatty cold water fish such as wild salmon (see 
Table 3). Fish oil supplements usually contain both EPA (usually the dominant fatty acid) 
and DHA which are extracted from krill and microalgae (Head, 2009). DHA and EPA 
can also be synthesized in the body from ALA, the less bioavailable plant n-3 fatty acid. 
However, studies suggest the capacity to convert ALA to EPA and DHA in humans is 
very low. It is estimated that only about 5-10% of ALA is converted to EPA and about 2-
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5% is converted to DHA in healthy adults. In addition, the conversion rate is lowered by 
40-50% when combined with a diet that is relatively high in n-6 F As (Gerster, 1998). The 
most abundant n-3 fatty acid in most Western diets, ALA is found in certain vegetable 
oils, green leafy vegetables, walnuts, flax and chia seeds (Hardman, 2002; Leitzmann et 
al., 2004). 
Table 3: DHA, EPA, and ALA content ofomega-3-rich foods. I tbsp oil= 13.6 g., 1 tbsp seeds/nuts= 
28.35 g. (USDA nutrient database release 24). 
Food Source DHA+EPA Food Source ALA 
(per serving) (ml!) (per tablespoon) (mg) 
Cod 134 Pumpkin seeds 51 
Catfish 151 Soybean oil 1,231 
Clams 241 Canola oil 1,302 
Shrimp 267 Walnut oil 1,414 
Flounder 426 Flaxseeds 2,350 
Pollock 460 Walnuts, English 2,574 
Tuna, canned 733 Chia seeds 5,055 
Salmon 1825 Flaxseed oil 7,249 
It appears that the type, rather than the amount, of dietary fat consumed may be 
more important in the pathogenesis of breast cancer (Grammatikos et al., 1994). The ratio 
of dietary n-6 to n-3 is especially important because both fatty acids compete with each 
other for an enzymatic substrate needed to produce prostaglandins (Bagga et al., 2002; 
Culp et al., 1979). The human population evolved on a ratio of dietary n-6 to n-3 fatty 
acids close to 1, but that ratio is now about 15/1 to 16. 7 /1 in a typical Western diet 
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(Simopoulos, 2001). Omega-3 fatty acids exhibit anti-inflammatory effects by 
suppressing inflammatory cytokines such as interleukin 1 ~ (IL-1 ~), interleukin 6 (IL-6) 
and tumor necrosis factor (TNFa). N-6 fatty acids, on the other hand, are pro-
inflammatory. This observation is one reason why a lower dietary ratio of n-6 to n-3 is 
beneficial to people suffering from or at risk for diseases characterized by inflammation 
(Simopoulos, 2006). Some of the diseases that have been linked to diets rich in n-6 fatty 
acids and low in n-3 fatty acids include cardiovascular disease, hypertension, renal 
disease, diabetes, arthritis, ulcerative colitis, Crohn's disease, and cancer (Simopoulos, 
1999). 
Epidemiological studies have revealed a negative correlation between the intake 
of n-3 fatty acids and cancer risk. Omega 3 fatty acids have clear anticarcinogenic 
properties in animal models and in vitro, while omega 6 fatty acids tend to have the 
opposite effect by increasing cancer risk (Grammatikos et al., 1994; Fay et al., 1997; 
Hardman, 2002; Connolly et al., 1999). Not surprisingly, epidemiologic research has 
revealed lower incidences of breast cancer in locations where fish makes up a larger part 
of the diet, and higher incidences where vegetable oils are consumed in greater quantities, 
such as the U.S. (Grammatikos et al., 1994). As the diets of Japanese women have 
become more westernized and lower in n-3 fatty acids, death rates from breast cancer in 
this population have been on the rise (Lands et al., 1990). 
Studies have noted a negative correlation associated with risk for other types of 
cancers as well, including prostate cancer. A 12-year follow-up study of nearly 50,000 
men revealed that the consumption of fish more than three times per week was associated 
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with a reduced risk of prostate cancer. In addition, it was noted that for every 0.5 g 
increase of dietary marine fatty acids per day, overall risk of metastatic cancer decreased 
by 24% (Augustsson et al., 2003). 
Assessment of the dietary intakes of 3081 breast cancer survivors participating in 
the Women's Healthy Eating and Living (WHEL) study revealed that women with the 
highest intakes of EPA and DHA from food (> 73 mg/day) had a 25% reduction in 
further breast cancer events as compared with the group with the lowest intakes. Higher 
intakes of dietary EPA and DHA also correlated with a reduced risk of all-cause mortality 
in a dose-dependent manner (Patterson et al.,2011 ). The results of another study 
comparing the dietary patterns of 358 breast cancer patients and 360 controls with no 
history of cancer found that high intakes of fatty fish were associated with reduced breast 
cancer risk (Kim et al., 2009). 
The analysis of breast adipose tissue is an accurate and practical estimate of 
dietary fat intake. A case-control study carried out in France examined the fatty acid 
composition of breast adipose tissue from 329 patients with either breast cancer or benign 
breast disease and determined that n-3 fatty acid levels were inversely associated with 
breast cancer risk (Maillard et al., 2002). Another study comparing 73 breast cancer 
patients to 74 controls found that the levels of n-6 PUF A in the breast adipose tissue was 
significantly higher in the breast cancer patients as compared with the controls (Bagga et 
al., 2002). 
14 
Research on animal models has confirmed the protective effects of DHA as it 
relates to carcinogenesis, as well as its effect on breast tumor growth and metastasis. One 
study revealed that mice fed a diet rich in ALA from flaxseed displayed a decreased 
growth rate of mammary tumors and an inhibition of tumor metastasis (Chen et al., 
2002). A novel study using a combined treatment of fish oil (Maxepa) and 1,25-
dihydroxyvitamin D3 on rats with DMBA-induced breast cancer revealed a significant 
decrease in the amount and incidence of mammary tumors as compared to effects of the 
compounds administered alone. Researchers found that the chemotherapeutic effects of 
daily oral doses of fish oil and vitamin D3 occurred as a result of reduced cell 
proliferation and decreased levels of inducible nitric oxide synthase (iNOS) (Chatterjee 
et al., 2010). 
In vitro studies have revealed that omega-3 fatty acids in the form of DHA 
significantly increase the rate of apoptosis and differentiation in human MCF-7 breast 
cancer cells and inhibit their growth (Kang et al., 2010). One study evaluated some of the 
mechanisms behind DHA-induced apoptosis in this cell line and found that it occurs via 
reactive oxygen species (ROS) formation and activation of caspase 8 (Kang et al., 2010). 
A similar study using MCF-7 cells confirmed this effect and found that as apoptosis was 
induced, so was the expression of procaspase-8 and bcl-2 (Corsetto et al., 2011). While 
DHA has been shown to reduce the growth ofMCF-7 breast cancer cells by up to 50% in 
a dose-dependent manner (6-30 µM), DHA at levels below 24 µM had no effect on 
noncancerous human mammary cell lines (Grammatikos et al., 1994). 
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Although the mechanisms behind the chemotherapeutic effects of DHA are not 
well defined, evidence suggests that one reason for the opposing effects essential fatty 
acids have on tumor expression is due to prostaglandin E2 (an eicosanoid), which is 
known to enhance tumor growth. While prostaglandin E2 originates from n-6 fatty acids, 
n-3 fatty acids inhibit its production (Norman et al., 2003). Most of the various proposed 
mechanisms for the anticancer effects of DHA including the reduction of cell 
proliferation and neoplastic transformation as well as enhanced apoptosis and 
antiangiogenicity are either directly or indirectly related to their inhibition of eicosanoid 
production from n-6 fatty acids (Kang et al., 2010). A study using the breast cancer cell 
line MDA-MB-231 discovered that cell growth was stimulated by n-6 and n-9 PUF As, 
and inhibited by n-3 PUF As, particularly DHA and to a lesser extent, EPA (Rose & 
Connolly, 1990). 
5-Fluorouracil 
5-Fluorouracil is an antimetabolite that induces apoptosis by targeting the enzyme 
thymidylate synthase (TS) which disrupts DNA synthesis within the cell. It has been 
shown to work synergistically with DHA to slow cell growth in colon cancer cells more 
effectively than either compound administered alone, and was effective in low-dose 
combinations (Calviello et al., 2005). A study carried out on 56 breast cancer patients 
revealed an association between the levels of DHA in mammary adipose tissue and the 
patient's response to chemotherapy treatment. After a combined treatment with 
vindesine, cyclophosphamide, and 5-Fluorouracil, it was reported that the patients with 
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the largest decrease in tumor size following treatment were the ones with elevated levels 
of DHA (Bougnoux et al., 1999). 
The combined therapeutic effect of vitamin D and 5-Fluorouracil has also been 
found to produce some promising results in vitro. A study published in 2010 revealed that 
vitamin D enhanced the susceptibility of human colon cancer cells to the effects of 5-
Fluorouracil by activating the calcium-sensing receptor which decreases the expression of 
survivin and thymidylate synthase within the cell. Since 5-Fluorouracil works by 
targeting thymidylate synthase, a lower expression of TS increased the efficacy of the 
drug (Liu et al., 2010). Another study using human MCF-7 cells sought to determine 
whether pretreating the cells with vitamin D and/or all-trans-retinoic acid (ATRA) would 
increase the efficacy of the cytotoxic drugs paclitaxel (Taxol) and Adriamycin. The 
researchers concluded that vitamin D and A TRA both increased cellular sensitivity to the 
chemotherapy drugs, and this occurred when administered both in combination and 
individually (Wang et al., 2000). In another study, researchers pretreated MCF-7 cells 
with 10 nM 1,25(0H)2D3 before exposing them to doxorubicin and observed a 
synergistic effect. Interestingly, in this study 1,25(0H)2D3 exhibited no effect on cell 
number and viability on its own (Ravid et al., 1999). 
In summary, vitamin D and DHA appear to have chemotherapeutic properties that 
are evident both in vitro and in vivo. Few studies have evaluated the combined effects of 
these compounds, which was a primary objective of ours. The ability of vitamin D and/or 
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DHA to exhibit anticancer effects in vitro suggests the possibility of a promising clinical 
application for breast cancer patients. 
18 
References 
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-
Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer 
- results of a large case-control study. Carcinogenesis. 2008; 29: 93-99. 
American Institute for Cancer Research/World Cancer Research Fund. Food, Nutrition 
and the Prevention of Cancer: A Global Perspective (American Institute for 
Cancer Research, Washington, 1997). 
Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, 
Giovannucci E. A prospective study of intake of fish and maride fatty acids and 
prostate cancer. Cancer Epidemiology, Biomarkers & Prevention. 2003; 12:64. 
Bagga D, Anders KH, Wang H, Glaspy JA. Long-chain n-3-to-n-6 polyunsaturated fatty 
acid ratios in breast adipose tissue from women with and without breast cancer. 
Nutrition and Cancer. 2002; 42(2): 180-185. 
Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with 
refractory malignancies. Cancer. 2001; 91 :2431-9. 
Bertone-Johnson ER, Chen WY, Halick MF, Hollis BW, Colditz GA, Willett WC, 
Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and 
risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2005; 
14: 1991-1997. 
Bougnoux P, Hajjaji N, Farrasson MN, Giraudeau B, Couet C, Le Floch 0. Improving 
outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a 
phase II trial. British Journal of Cancer. 2009; 101: 1978-1985. 
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk 
estimates for BRCAl mutation carriers identified in a risk evaluation program. 
Journal of the National Cancer Institute. 2002; 94: 1365-72. 
Chen J, Stavro M, Thompson LU. Dietary flaxseed inhibits human breast cancer growth 
and metastasis and downregulates expression of insulin-like growth factor and 
epidermal growth factor receptor. Nutrition and Cancer. 2002; 43(2): 187-192. 
Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D 
supplementation and the risk of breast cancer. Journal of the National Cancer 
Institute. 2008; 100:1581-1591. 
Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of 
vitamin Din breast cancer. Endocrine-Related Cancer 2001; 9:45-59. 
Connolly JM, Gilhooly EM, Rose DP. Effects ofreduced dietary linoleic acid intake, 
alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-
231 breast cancer cell growth and apoptosis in nude mice. Nutrition and Cancer. 
1999; 35(1):44-49. 
Corsetto PA, Montorfano G, Zava S, Jovenitti IE, Cremona A, Berra B, Rizzo AM. 
19 
Effects ofn-3 PUFAs on breast cancer cells through their incorporation in plasma 
membrane. Lipids in Health and Disease. 2011; 10:73. 
Crew KD, Gammon MD, Steck SE, et al. Association between plasma 25-
hydroxyvitamin D and breast cancer risk. Cancer Prevention Research. 2009; 
2:598-604. 
Culp BR, Titus BG, Lands WE. Inhibition of prostaglandin biosynthesis by 
eicosapentaenoic acid. Prostaglandins and Medicine. 1979; 3 :269-278. 
Deeb KK, Trump DL, Johnson CS. Vitamin D signaling pathways in cancer: potential for 
anticancer therapeutics. Nature Reviews. 2007; 7:684-700. 
DeLuca HF. Overview of general physiologic features and functions of vitamin D. 
American Journal of Clinical Nutrition. 2004; 80(suppl): 1689S-96S. 
Fay MP, Freedman LS, Clifford CK, Midthune DN. Effect of different types and amounts 
of fat on the development of mammary tumors in rodents: a review. Cancer 
Research. 1997; 57:3979-3988. 
Ford HL, Sclafani RA, Degregori J. Cell cycle regulatory cascades. In: Stein GS & 
Pardee AB, eds. Cell cycle and growth control: Biomolecular regulation and 
cancer. Hoboken, NJ: John Wiley & Sons; 2004: 95-128. 
Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and 
breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening 
trial. Cancer Epidemiology, Biomarkers & Prevention. 2008; 17:889-894. 
Gerster H. Can adults adequately convert a-linolenic acid (18:3 n-3) to eicosapentaenoic 
acid (20:5 n-3) and docosahexaenoic acid (22:6 n-3)? International Journal for 
Vitamin and Nutrition Research. 1998; 68:159-73. 
20 
Grammatikos SI, Subbaiah PV, Victor TA, Miller WM. n-3 and n-6 fatty acid processing 
and growth effects in neoplastic and non-cancerous human mammary epithelial 
cell lines. British Journal of Cancer. 1994; 70:219-227. 
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70. 
Hardman WE. Omega-3 fatty acids to augment cancer therapy. The Journal of Nutrition. 
2002; 132:3508S-3512S. 
Head K. (Ed) Docosahexxaenoic acid (DHA). Alternative Medicine Review. 2009; 
14(4):391-399. 
Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-
hydroxycholecalciferol response to extended oral dosing with cholecalciferol. 
American Journal of Clinical Nutrition. 2003; 77:204-10. 
Holick, MF. Vitamin D and health: evolution, biologic functions, and recommended 
dietary intakes for vitamin D. Clinical Reviews in Bone and Mineral Metabolism. 
2009; 7:2-19. 
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. 
Cancer Journal for Clinicians. 2011; 61 :69-90. 
Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Cancer Journal for Clinicians. 
2010; 60:277-300. 
Jensen EV. From chemical warfare to breast cancer management. Nature Medicine. 2004; 
10(10): 1018-1021. 
Kang KS, Wang P, Yamabe N, Fukui M, Jay T, Zhu BT. Docosahexaenoic acid induces 
apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species 
formation and caspase 8 activation. Plos One. 2010; 5(4):e10296. 
Kemmis CM, Salvador SM, Smith KM, Welsh J. Human mammary epithelial cells 
express CYP27Bl and are growth inhibited by 25-hydroxyvitamin D-3, the major 
circulating form of vitamin D-3. The Journal of Nutrition. 2006; 136:887-892. 
Kim J, Lim SY, Shin A, Sung MK, Ro J, Kang HS, Lee KS, Kim SW, Lee ES. Fatty fish 
and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case control 
study. BMC Cancer. 2009; 9:216. 
Lands WEM, Hamazaki T, Yamazaki K, Okuyama H, Sakai K, Goto Y, Hubbard VS. 
Changing dietary patterns. American Journal of Clinical Nutrition. 1990; 51 :991-
3. 
21 
Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium 
supplementation reduces cancer risk: results of a randomized trial. American Journal of 
Clinical Nutrition.2007; 85:1586-1591. 
Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, 
Giovannucci EL. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate 
cancer. Amercian Journal of Clinical Nutrition. 2004; 80:204-216. 
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88:323-331. 
Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is 
dependent on season of diagnosis and sunlight exposure. International Journal of 
Cancer. 2006; 119:1530-1536. 
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma 
cells in a calcium-sensing receptor-dependent manner: downregulates malignant 
cell behavior and the expression of thymidylate synthase and survivin and 
promotes cellular sensitivity to 5-FU. International Journal of Cancer. 201 O; 
126:631-639. 
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. Journal of 
Cancer. 2010; 1: 101-107. 
Madid Z, Karimi A, Molanae S, Asadi-Lari M. BRCAl protein expression level and 
CD44+ phenotype in breast cancer patients. Cell Journal. 2011; 13(3):155-162. 
Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonniere F, Body G, Le 
Floch 0, Chajes V. N-3 and n-6 fatty acids in breast adipose tissue and relative 
risk of breast cancer in a case-control study in Tours, France. International 
Journal of Cancer. 2002; 98: 78-83. 
MangelsdorfD, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, 
Kastner P, Mark M, Chambon P, Evans R. The nuclear receptor superfamily: the 
second decade. Cell 83: 835-839, 1995 
Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in 
breast cancer cells is inhibited by bcl-2 but does not involve known caspases of 
p53. Cancer Research. 1999; 59:4848-4856. 
McCullough ML, Stevens VL, Patel R, Jacobs EJ, et al. Serum 25-hydroxyvitamin D 
concentrations and postmenopausal breast cancer risk: a nested case control study 
in the cancer prevention study-II nutrition cohort. Breast Cancer Research. 2009; 
11 :R64. 
22 
Melamed ML, Michos ED, Post M, Astor B. 25-hydroxyl vitamin D levels and the risk of 
mortality in the general population. Archives of Internal Medicine. 2008; 168(15): 
1629-1637. 
Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: 
mutation and nuclear exclusion. Proceedings of the National Academy of Sciences 
of the United States of America. 1992;89: 7262-7266. 
Moyad MA. Vitamin D: A rapid review. Urologic Nursing. 2008; 28(5):343-349,384. 
Nelms M, Sucher K, Long S. Nutrition therapy and pathophysiology. Belmont, CA: 
Brooks/Cole, 2007. 
Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, Rivlin R, 
Simopoulos A, Wargovich MJ, Weisburger EK, Zeise} SH. The role of dietary 
supplements during cancer therapy. Journal of Nutrition. 2003; 133: 3794S-
3799S. 
Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer 
Research and Treatment. 1998; 51 :227-238. 
Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 
1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. 
Urologic Oncology. 1995; 195-198. 
Pardee, AB. Cell fates. In: Stein GS & Pardee AB, eds. Cell cycle and growth control: 
Biomolecular regulation and cancer. Hoboken, NJ: John Wiley & Sons; 2004:3-
13. 
Patterson RE, Flatt SW, Newman VA, Natarajan L, Rock CL, Thomson CA, Caan BJ, 
Parker BA, Pierce JP. Marine fatty acid intake is associated with breast cancer 
prognosis. Journal of Nutrition. 2011; 141:201-206. 
Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman 
UA, Koren R. 1,25-dihydroxyvitamin D3 enhaces the susceptibility of breast 
cancer cells to doxorubicin-induced oxidative damage. Cancer Research. 1999; 
59(4):862-7. 
Reed JC, Green DR. (2011). Apoptosis: physiology and pathology. New York, NY: 
Cambridge University Press. 
23 
Rejnmark L, Tietze A, Vestergaard P, et al. Reduced prediagnostic 25-hydroxyvitamin D 
levels in women with breast cancer: a nested case-control study. Cancer 
Epidemiology, Biomarkers & Prevention. 2009; 18:2655-2660. 
Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the 
prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes and 
Control. 2004; 15:149-158. 
Rose DP, Connolly JM. Effects of fatty acids and inhibitors of eicosanoid synthesis on 
the growth of a human breast cancer cell line in culture. Cancer Research. 1990; 
50:7139-7144. 
Ross CA, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu 
RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses 
SA. The 2011 report on dietary reference intakes for calcium and vitamin D from 
the institute of medicine: what clinicians need to know. Journal of Clinical 
Endocrinology and Metabolism. 2001; 96(1):53-58. 
Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J. 
Comparative effects of l ,25(0H)2D3 and EB 1089 on cell cycle kinetics and 
apoptosis in MCF-7 breast cancer cells. Breast Cancer Research and Treament. 
1997; 42(1):31-41. 
Simopoulos AP. Essential fatty acids in health and chronic disease. American Journal of 
Clinical Nutrition. 1999; 70(suppl):560S-9S. 
Simopoulos AP. The Mediterranean diets: what is so special about the diet of Greece? 
The scientific evidence. Journal of Nutrition. 2001; 131:3065S-3073S. 
Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic 
variation: nutritional implications for chronic diseases. Biomedicine & 
Pharmacotherapy. 2006; 60:502-507. 
Stiff L, Miller SM. Vitamin D: bringing light to the issue. MLO. 2009: 24-30. 
Swami S, Krishnan AV, Feldman D. la,25-dihydroxyvitamin D3 down-regulates 
estrogen receptor abundance and suppresses estrogen actions in MCF-7 human 
breast cancer cells. Clinical Cancer Research. 2000; 6: 3371-3379. 
Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition 
of breast cancer cells: gene expression patterns assessed by cDNA microarray. 
Breast Cancer Research and Treatment. 2003; 80:49-62. 
24 
U.S. Department of Agriculture, Agricultural Research Service. 2011. USDA National 
Nutrient Database for Standard Reference, Release 24. Nutrient Data Laboratory 
Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl (accessed 16 April 2012). 
Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-dihydroxyvitamin D3 and 
all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell 
death. Cancer Research. 2000; 60:2040-2048. 
Wang S, El-Deiry WS. Apoptosis signaling in normal and cancer cells. In: Stein GS & 
Pardee AB, eds. Cell cycle and growth control: Biomolecular regulation and 
cancer. Hoboken, NJ: John Wiley & Sons; 2004:95-128. 
Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and 
antiestrogens. Biochem Cell Biol. 1994; 72(11-12):537-45. 
Welsh J. Targets of vitamin D receptor signaling in the mammary gland. Journal of Bone 
and Mineral Research. 2007; 22:V86-V90. 
Wietzke JA, Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 
1,25-dihydroxyvitamin D3 actions in human breast cancer cells. Journal of 
Steroid Biochemistry & Molecular Biology. 2003; 84:149-157. 
CHAPTER II 
THE EFFECTS OF 1,25-DIHYDROXYVITAMIN D3, DOCOSAHEXAENOIC ACID 
AND 5-FLUOROURACIL ON HUMAN BREAST CANCER CELLS 
Liv A. Engelsen, Susan Hawk, Kelly Pritchett, Virginia Bennett 
li v.engelsen@gmail.com 
Central Washington University 
25 
26 
Abstract 
It is well documented that vitamin D and DHA have antiproliferative effects on a 
variety of human cancers, including breast cancer. Studies have shown that a combination 
approach to cancer treatment is more effective than any one treatment administered 
alone. The purpose of our research was to determine whether the combination of vitamin 
D and DHA would demonstrate increased growth inhibition in human MCF-7 breast 
cancer cells. We also sought to determine whether these compounds would increase 
cellular sensitivity to the antimetabolite chemotherapy drug 5-Fluorourocil, which is 
commonly used in the treatment of breast cancer. The ability of either vitamin D or DHA 
to enhance the effects of a chemotherapy agent could translate to a decreased drug dosage 
requirement and/or a reduction in treatment time for the patient. This would be of benefit 
due to the undesirable side effects patients typically experience from cytotoxic drugs. In 
this study, human mammary epithelial cells from the MCF-7 cell line were treated with 
25 µM DHA, 1 µM calcitriol, and 15 µM 5-Fluorourocil alone and in multiple 
combinations for 72 hours. Both DHA and 5-Fluorouracil slowed growth significantly (p 
< 0.05). In contrast, vitamin D did not inhibit cell growth at 1 µM. The combination of 
vitamin D and DHA inhibited cell growth slightly more than DHA alone. Interestingly, 
DHA was just as effective as 5-Fluorouracil at inhibiting cell growth. These results 
suggest that DHA may be just as efficacious as 5-Fluorouracil in slowing breast cancer 
progression and therefore may suggest a dietary approach to breast cancer treatment with 
low toxicity. 
27 
Introduction 
Although breast cancer rates have been declining over the past twenty years due 
to early detection and treatment efforts, it still remains the leading cause of cancer death 
among women (Jemal et al., 2010). Established risks for developing breast cancer include 
obesity, reproductive factors, alcohol consumption, physical inactivity, exogenous 
hormones and possibly diet (Parkin et al., 2002). It has been estimated that nutrition 
contributes to carcinogenesis in about one-third of the cancers in developed countries, 
making dietary factors one of the top preventable causes of cancer (Peto, 2001 ). Recent 
estimates further support this relationship and suggest that nutrition and lifestyle factors 
may contribute to onset in nearly 80% of prostate and breast cancer cases (Go et al., 
2001). 
The relationship between vitamin D status and disease onset and prognosis has 
been a recent area of interest in all levels of research. A positive association between 
vitamin D status and reduced breast cancer risk has been noted (Abbas et al., 2008; Crew 
et al., 2009; Rejnmark et al., 2009). However, some studies failed to establish this 
relationship (Chlebowski et al., 2008; Freedman et al., 2008; McCullough et al., 2009). 
One study evaluating data from NHANES III observed no relationship between vitamin 
D status and cancer death, but did find that individuals with vitamin D levels of <17.8 
ng/ml had a 26% higher risk of all-cause mortality (Melamed et al., 2008). Other studies 
have indicated that the lowest number of cancer mortalities occurred in cancer cases that 
were diagnosed during the summer and fall, when serum vitamin D3 levels are typically 
the highest (Robsahm et al., 2004; Lim et al., 2006). 
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Omega 3 fatty acids also have clear anticarcinogenic properties in animal models 
and in vitro, while omega 6 fatty acids tend to have the opposite effect and can increase 
cancer risk (Grammatikos et al., 1994; Fay et al., 1997; Hardman, 2002). Since much of 
the essential fatty acids consumed in the diet get incorporated directly into cell 
membranes, they have a significant impact on cellular control and regulation. These fatty 
acids are not interchangeable, and by competing with each other for the substrate 
necessary to produce prostaglandins they promote contrasting effects on inflammation in 
the body. Therefore, the ratio of essential fatty acids consumed in the diet may be a key 
in the prevention of cancer. Not surprisingly, epidemiologic research has revealed lower 
incidences of breast cancer in locations where fish (rich sources of n-3 fatty acids) 
comprise a larger part of the diet, and higher incidences where vegetable oils (rich 
sources of n-6 fatty acids) are consumed in greater quantities, such as the U.S. 
(Grammatikos et al., 1994). 
Studies have revealed that both vitamin D and omega 3 fatty acids in the form of 
DHA significantly increase the rate of apoptosis in human MCF-7 breast cancer cells 
while inhibiting their growth (Kang et al., 2010; Deeb et al., 2007). While the exact 
mechanisms behind the antineoplastic effects of vitamin D and DHA are still under 
investigation, the results of numerous research studies show that both compounds have 
valuable clinical potential. Many studies have shown that the combination approach to 
cancer treatment is more effective than any one compound administered alone. Although 
many studies have been done in vitro to examine the individual effects of vitamin D and 
DHA on cancer cells, few have studied their combined therapeutic outcome. 
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Treatment for breast cancer typically involves the combination of chemotherapy 
drugs which have multiple side effects and are seldom well tolerated. Therefore, any 
supplemental and non-toxic treatment with the potential to increase tumor sensitivity to 
anti-cancer drugs may contribute to a favorable prognosis and treatment outcome 
(Bougnoux et al., 2009). Epidemiologic and experimental research suggests that the 
administration of moderate doses of vitamin D (l ,25(0H)iD3) in the form of calcitriol 
and/or omega-3 fatty acids in the form of docosahexaenoic acid (DHA) have potential in 
a clinical setting. These compounds could potentially reduce the amount of 
chemotherapeutic drugs needed or decrease the length of chemotherapy treatment 
required for cancer patients. The primary objective of our research was to evaluate the 
efficacy of vitamin D and DHA to synergistically slow cell growth in human breast 
cancer cells. Another purpose was to determine if DHA and/or vitamin D could enhance 
the sensitivity of the MCF-7 cells to 5-Fluorouracil, a chemotherapy drug frequently used 
in breast cancer treatment. 
Materials and Methods 
Cell Culture 
Human mammary carcinoma cells from the MCF-7 cell line were obtained from 
the American Type Institute (Rockville, MD). The MCF-7 cells were cultured in 20 ml of 
Dulbecco's Modified Eagle Media (DMEM) along with 10% fetal bovine serum (FBS) 
and 1 % antibiotic (50% penicillin and 50% streptomycin). They were maintained in an 
incubator at 37°C with 5% C02 until confluent. 
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Chemicals and Reagents 
Docosahexaenoic Acid (DHA), vitamin D (Calcitriol), and 5-Fluorouracil were 
obtained from Fisher Scientific (Pittsburgh, PA). These compounds were dissolved in 
ethanol and the stock solutions were stored in the dark at -l 8°C. Both DHA and 
l,25(0H)2D3 were further diluted with Dulbecco's Modified Eagle Media (DMEM) with 
10% FBS and 1 % antibiotic prior to treatment. 5- Fluorouracil was dissolved in ethanol 
just prior to treatment. 
Treatments 
A total of six trials were conducted beginning on confluent cells. Once the cells 
reached confluency, they were counted using trypan blue and a hemacytometer and 
divided into two 96-well plates at a concentration of 5,000 cells per well. Cells were 
incubated and allowed to adhere for 24 hours. After 24 hours, media was removed and 
replaced with fresh media. Treatments were then applied to the two plates with 5,000 
cells per well, and they were incubated for 72 hours (see Table 1 ). 
Table 1 : Treatments 
1 0.1% EtOH (control) 
2 1 µM Calcitriol 
3 25 µMDHA 
4 1 µM Calcitriol + 25 µM DHA 
5 15 µM 5-Fluorouracil 
6 1 µM Calcitriol + 15 µM 5-Fluorouracil 
7 25 µM DHA + 15 µM 5-Fluorouracil 
8 1 µM Calcitriol + 25 µM DHA + 15 µM 5-Fluorouracil 
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Cell Viability Assay 
After the 72-hour incubation period, the cells were treated with a tetrazolium salt 
solution and measured for viability using a quantitative colorimetric assay and read on a 
BioTek Synergy 2 microplate reader (Winooski, VT) at 490 nm. 
Statistical Analysis 
Statistical analysis was carried out using SPSS version 18.0 (Chicago, IL). A one-
way analysis of variance (ANOV A) was used to identify statistical significance between 
treatment groups as compared to control values (p ~ 0.05). A Bonferroni post hoc was 
applied to further evaluate the significant differences between treatment groups. 
Results 
The chemotherapeutic effects of DHA, calcitriol, and 5-Fluorouracil, alone and in 
various combinations, were assessed with the use of a cell viability assay following a 72-
hour treatment period. Results indicate that all but two treatments significantly decreased 
cell viability compared to the control (p < 0.05). Treatment with calcitriol alone and in 
combination with 5-Fluorouracil did not significantly alter cell viability (Fig. 1 and 2). 
32 
120 
,_.._ 
0 
r... 100 
-c 0 
CJ 
.... 80 0 
-c QI 
(,I 
60 r... QI 
c.. 
'-' 
~ 40 
-
·r;; 
c 
QI 
"O 20 
-Qj 
u 
0 
03 
Cell viability as compared to EtOH control 
OHA SF 
~1-.··· 
03/DHA 
Treatment 
03/SF OHA/5F 03/DHA/SF 
'" ___ " __ ·,~-~--'"'"'"'""" 
Figure 1. Cell viability as compared to EtOH are represented as mean absorbance 
percentages and represent the results of six trials. Bars with an asterisk are significantly different from the 
control (p < 0.05). 
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Figure 2. Mean light absorbance at 490 nm for three trials (six plates total). Cell viability was evaluated 
using a CCK-8 assay after a 72 hour treatment period. Higher absorbance values represent greater cell 
viability. 
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DHA 
Consistent with the literature, treatment ofMCF-7 cells with 25 µM DHA alone 
decreased cell viability by ~57% (p < 0.05). When combined with 1,25(0H)2D3 and 5-
Fluorouracil, a significant reduction in cell viability occurred after 72 hours (p < 0.05). 
DHA was as effective alone as it was when combined with other compounds. However, 
although not statistically significant (p = 1.00), vitamin D and DHA appeared to decrease 
cell viability slightly more than when either compound was administered alone, 
suggesting a possible synergistic effect. Interestingly, there was no significant difference 
between DHA and 5-Fluorouracil (p = 1.00), revealing that DHA was just as effective as 
5-Fluorouracil in reducing cell growth. 
Vitamin D 
Treatment ofMCF-7s with 1µM1,25(0H)iD 3 for 72 hours did not reveal a 
significant reduction in cell viability (p = 1.00). Although not statistically significant, 
cells treated with vitamin D alone actually had an increased viability as compared to the 
control. Overall, vitamin D displayed an 11.5% increase in cell density as compared to 
the control. These observations are unusual and inconsistent with similar research studies. 
When compared to cells treated with 5-Fluorouracil alone, those treated with the 
combination of 5-Fluorouracil and vitamin D displayed a significant increase in cell 
viability (p < 0.05). This indicates that the growth-inhibitory effects of 5-Fluorouracil 
were not sufficient to reduce the apparent increase in cell viability induced by 
l ,25(0H)iD3 . 
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5-Fluorouracil 
At a concentration of 15 µM, 5-Fluorouracil significantly reduced cell density of 
MCF-7s after 72 hours of treatment (p < 0.05). Overall, 5-FU slowed cell growth by 
~55% which is comparable to the growth inhibitory effects of DHA. 5-Fluorouracil did 
not appear to be any more effective when paired with vitamin D and/or DHA. 
Discussion 
The purpose of this study was to evaluate the chemotherapeutic effects of vitamin 
D (l ,25(0H)2D3) and docosahexaenoic acid (DHA) on breast cancer cells both 
individually and in combination. We also sought to determine whether these compounds 
would increase sensitivity to the chemotherapeutic drug 5-Fluorouracil in the MCF-7 cell 
line. Our findings support the notion that DHA slows breast cancer cell growth both 
alone and in combination with vitamin D and 5-Fluorouracil. Interestingly, DHA is just 
as effective as 5-Fluorouracil in slowing cancer progression. In contrast to other research 
findings, 1,25(0H)2D3 did not alter cell viability when administered alone. 
The effects of DHA may be mediated by a number of different cellular 
mechanisms, many of which are not yet fully understood. Omega-3 fatty acids can inhibit 
the proliferation of MCF-7 cells and promote apoptosis and differentiation. In addition, 
DHA may suppress neoplastic formation and decrease angiogenesis in animal models 
(Connolly et al., 1999). These actions may be due in part to the ability of omega-3 fatty 
acids to interfere with the production of ecoisanoids from omega-6 fatty acids. In 
particular, n-3 F As inhibit the production of prostaglandin E2 (PGE2), an inflammatory 
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eicosanoid derived from arachidonic acid (AA) that increases estrogen production and 
has been shown to promote breast cancer cell growth. In addition to producing PGE2, AA 
also promotes the growth of tumor cells by stimulating mitosis through the activation of 
protein kinase C, which is inhibited by DHA and EPA (Rose & Connolly, 1990). 
To further elucidate the strong anticancer nature ofDHA in the MCF-7 cell line, 
researchers evaluated the induction of oxidative stress and apoptosis as mediators of cell 
death. They observed that the removal of caspase 8 in these cells completely abolished 
DHA-induced cell death. Without the accumulation of reactive oxygen species (ROS), 
MCF-7 cells were protected from apoptosis. This suggests that caspase 8-mediated 
apoptosis is the primary form of cell death induced by DHA, and it is mediated by the 
accumulation of ROS (Kang et al., 2010). 
Although the amount of DHA used in this study exceeds normal physiological 
levels, these findings support the notion that the protective nature of DHA may be of 
value for the prevention and treatment of breast cancer. DHA may be of additional 
benefit in reducing the risk of cachexia, a common side effect of cancer treatment that 
occurs as a result of changes in energy expenditure. This wasting away of lean muscle 
mass is not easily corrected by increasing caloric intake alone (Moses et al., 2004). 
Reversal of cachexia and weight stabilization has been observed with the administration 
of dietary EPA and DHA in cancer patients (Moses et al., 2004; Fearon et al., 2003), 
suggesting another therapeutic use for n-3 fatty acids. 
36 
Although we did not observe 1,25(0H)2D3 exhibiting anticancer effects when 
administered alone, a possible synergism may exist between 1,25(0H)2D3 and DHA. 
Studies have indicated that the chemotherapeutic effects of DHA on cancer cells are 
suppressed when combined with antioxidants and enhanced when combined with 
prooxidants (Gonzalez et al., 1991). Treating MCF-7 cells with the antioxidant a-
tocopherol was effective in protecting them from DHA-induced cell death (Kang et al., 
2010). Researchers also determined that 1,25(0H)2D3 acts as a prooxidant in cancer cells 
which may explain our observation of a greater reduction in viability when cells were 
treated with 1,25(0H)2D3 and DHA in combination (Koren et al., 2001 ). Further research 
should be conducted to evaluate the combined effects of DHA and prooxidants such as 
1,25(0H)2D3. 
Rather than causing a reduction in cell viability, results from this study revealed 
that a single treatment of 1,25(0H)2D3 tended to increase cell viability. One possible 
explanation for this is that the timecourse was inadequate to facilitate the slower kinetics 
of 1,25(0H)2D3 in vitro. Previous studies have observed that apoptosis in MCF-7 cells 
first occurs after the third day of treatment with 1,25(0H)2D3 due to intracellular 
transformations that must occur first (James et al., 1996). In addition, several studies 
grew MCF-7 cells in medium containing 1,25(0H)2D3 prior to the incubation period 
(Narvaez & Welsh 2001; Wang et al., 2000). Thus, pretreatment with vitamin D may be 
necessary for the cells to become susceptible to the antiproliferative effects. 
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Breast cancer cells use multiple mechanisms to evade 1,25(0H)2Drmediated 
growth inhibition (Welsh, 2007) and several factors may have contributed to our 
observations. Vitamin D-mediated apoptosis in MCF-7 cells may be inhibited by the 
overexpression of the antiapoptotic protein Bcl-2 which is downregulated in response to 
1,25(0HhD3 . Researchers evaluated the effects of 1,25(0H)2D3 on MCF-7 cells 
overexpressing Bcl-2 and found that the cells were entirely protected from vitamin D-
mediated apoptosis (Mathiasen et al., 1999). The loss of VDR expression and/or changes 
in receptor co-regulators could also result in 1,25(0H)2D3 resistance (Welsh, 2007). 
Additionally, the expression of some oncogenes can potentially inhibit the 
anti proliferative effects of vitamin D (Agadir et al., 1999). 
It is well documented that both vitamin D and DHA have potential as anticancer 
agents in animal and cell culture models, but their clinical potential is still under 
investigation. Most studies first observe the antineoplastic effects of vitamin D with 
doses of 1 nm in vitro, a concentration that can be achieved in a clinical setting with 
intermittent oral dosing (Beer & Myrthue, 2004). Potential for the clinical application of 
DHA is also very promising. Bums et al. found that the maximum non-toxic dose of 
omega-3 fatty acids administered in a clinical setting was 0.3 g/kg per day or up to 21 
g/day for a 70 kg patient. Results from similar studies have indicated that only small 
amounts of n-3 fatty acids are needed to significantly influence cytokine production 
(Hardman, 2004). 
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In conclusion, our research supports a protective role of DHA on breast cancer 
progression, one that is comparable to that of 5-Fluorouracil. It has been well established 
that vitamin D has similar effects. In addition to their possible chemopreventive role, 
both compounds could potentially enhance the therapeutic effects of traditional breast 
cancer treatments in a clinical setting. Our data indicates the possibility of a synergism 
between DHA and 1,25(0H)2D3, yet additional studies are warranted to further evaluate 
this effect. In addition, clinical trials are necessary to evaluate the safety and efficacy of 
high intermittent dosing of these compounds as they apply to patient therapy. 
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